Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Normal subjects will receive unfractionated heparin followed by a single dose of PER977 with
dose escalation by cohort. Ten subjects enrolled in Cohort 4 will receive a single dose of
PER977 followed by a one-week washout and then will receive unfractionated heparin followed
by a single dose of PER977. The study will provide some insight into the doses that may be
required to reverse anticoagulation induced by heparin.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. Perosphere, Inc.